https://orcid.org/0000-0003-0396-2005
Key Points
Concept elicitation demonstrates symptoms and functions of cGVHD-associated sclerosis not captured by existing outcome measures.
The Lee Symptom Scale–Skin Sclerosis is a new PRO measure with content validity for cGVHD-associated sclerosis.
Subjects:
Transplantation
Abstract
Sclerosis is a highly morbid manifestation of chronic graft-versus-host disease (cGVHD), associated with distressing symptoms and significant long-term disability. A patient-reported outcome (PRO) measure for cGVHD-associated sclerosis is essential to advance therapeutic trials. We aimed to develop a PRO for adults with cGVHD-associated sclerosis and evaluate and refine its content validity. Adults aged ≥18 years with cGVHD-associated sclerosis participated in semistructured interviews to identify salient symptoms and functions. Sclerosis-relevant symptoms and functions from existing PROs were also used to prompt discussion of topics not spontaneously mentioned. Symptoms and functions (subcodes) of importance were clustered and mapped to overarching domains (codes) using inductive analysis, and candidate items were developed. Cognitive interviews were used to evaluate content validity of the items, response options, recall period, and respondent instructions. Thirty-six open-ended interviews, conducted to saturation, revealed the breadth of the patient experience with cGVHD-associated sclerosis including 5 overarching domains: (1) skin changes, (2) symptoms, (3) emotional and social functioning, (4) mobility restrictions, and (5) activity limitations. A pool of 54 items was tested and iteratively refined through cognitive debriefing interviews (n = 25). Phrasing changes were made to improve relevance and comprehension. One item was removed, and 2 items were added to address respondent feedback, resulting in 55 items. Results support the relevance, comprehensibility, and comprehensiveness of the provisional Lee Symptom Scale–Skin Sclerosis. Concept elicitation and cognitive interviewing have informed the development of the Lee Symptom Scale–Skin Sclerosis. Psychometric testing and determination of minimal clinically important differences are underway in an external cohort to validate the PROs.
Subjects:
Transplantation
References
1.
Zeiser
R
, Blazar
BR
. Pathophysiology of chronic graft-versus-host disease and therapeutic targets
. N Engl J Med
. 2017
;377
(26
):2565
-2579
.2.
Lee
SJ
, Nguyen
TD
, Onstad
L
, et al. Success of immunosuppressive treatments in patients with chronic graft-versus-host disease
. Biol Blood Marrow Transplant
. 2018
;24
(3
):555
-562
.3.
Pidala
J
, Kurland
B
, Chai
X
, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium
. Blood
. 2011
;117
(17
):4651
-4657
.4.
Pidala
J
, Kurland
BF
, Chai
X
, et al. Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium
. Haematologica
. 2011
;96
(10
):1528
-1535
.5.
Baker
KS
, Gurney
JG
, Ness
KK
, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the bone marrow transplant survivor study
. Blood
. 2004
;104
(6
):1898
-1906
.6.
Khera
N
, Storer
B
, Flowers
MED
, et al. Non-malignant late effects and compromised functional status in hematopoietic cell transplantation survivors
. J Clin Oncol
. 2012
;30
(1
):71
-77
.7.
Sun
CL
, Francisco
L
, Kawashima
T
, et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the bone marrow transplant survivor study
. Blood
. 2010
;116
(17
):3129
-3377
.8.
Syrjala
KL
, Langer
SL
, Abrams
JR
, et al. Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma
. JAMA
. 2004
;291
(19
):2335
-2343
.9.
Yalniz
FF
, Murad
MH
, Lee
SJ
, et al. Steroid refractory chronic graft-versus-host disease: cost-effectiveness analysis
. Biol Blood Marrow Transplant
. 2018
;24
(9
):1920
-1927
.10.
Janin
A
, Socie
G
, Devergie
A
, et al. Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases
. Ann Intern Med
. 1994
;120
(12
):993
-998
.11.
Arai
S
, Pidala
J
, Pusic
I
, et al. A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation
. Clin Cancer Res
. 2016
;22
(2
):319
-327
.12.
Skert
C
, Patriarca
F
, Sperotto
A
, et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome
. Haematologica
. 2006
;91
(2
):258
-261
.13.
Detrait
MY
, Morisset
S
, Peffault de Latour
R
, et al. Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)
. Bone Marrow Transplant
. 2015
;50
(2
):253
-258
.14.
Uhm
J
, Hamad
N
, Shin
EM
, et al. Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation
. Biol Blood Marrow Transplant
. 2014
;20
(11
):1751
-1757
.15.
Martires
KJ
, Baird
K
, Steinberg
SM
, et al. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease
. Blood
. 2011
;118
(15
):4250
-4257
.16.
Arora
M
, Cutler
CS
, Jagasia
MH
, et al. Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation
. Biol Blood Marrow Transplant
. 2016
;22
(3
):449
-455
.17.
Jachiet
M
, de Masson
A
, Peffault de Latour
R
, et al. Skin ulcers related to chronic graft-versus-host disease: clinical findings and associated morbidity
. Br J Dermatol
. 2014
;171
(1
):63
-68
.18.
Inamoto
Y
, Storer
BE
, Petersdorf
EW
, et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease
. Blood
. 2013
;121
(25
):5098
-5103
.19.
Fatobene
G
, Storer
BE
, Salit
RB
, et al. Disability related to chronic graft-versus-host disease after alternative donor hematopoietic cell transplantation
. Haematologica
. 2019
;104
(4
):835
-843
.20.
Hamilton
BK
, Storer
BE
, Wood
WA
, et al. Disability related to chronic graft-versus-host disease
. Biol Blood Marrow Transplant
. 2020
;26
(4
):772
-777
.21.
Wolff
D
, Radojcic
V
, Lafyatis
R
, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2020 highly morbid forms report
. Transplant Cell Ther
. 2021
;27
(10
):817
-835
.22.
Lee
SJ
, Wolff
D
, Kitko
C
, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report
. Biol Blood Marrow Transplant
. 2015
;21
(6
):984
-999
.23.
Jagasia
MH
, Greinix
HT
, Arora
M
, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report
. Biol Blood Marrow Transplant
. 2015
;21
(3
):389
-401.e1
.24.
Jacobsohn
DA
, Rademaker
A
, Kaup
M
, Vogelsang
GB
. Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD
. Bone Marrow Transplant
. 2009
;44
(12
):813
-819
.25.
Cardones
AR
, Sullivan
KM
, Green
C
, et al. Interrater reliability of clinical grading measures for cutaneous chronic graft-vs-host disease
. JAMA Dermatol
. 2019
;155
(7
):833
-837
.26.
Lee
SJ
, Cutler
C
, Blazar
BR
, Tu
A
, Yang
Z
, Pavletic
SZ
. Correlation of patient-reported outcomes with clinical organ responses: data from the Belumosudil chronic graft-versus-host disease studies
. Transplant Cell Ther
. 2022
;28
(10
):700.e1
-700.e6
.27.
Cutler
C
, Lee
SJ
, Arai
S
, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
. Blood
. 2021
;138
(22
):2278
-2289
.28.
Wolff
D
, Cutler
C
, Lee
SJ
, et al. Safety and efficacy of axatilimab at 3 different doses in patients with chronic graft-versus-host disease (AGAVE-201)
. Blood
. 2023
;142
(suppl 1
):1
.29.
Teh
C
, Onstad
L
, Lee
SJ
. Reliability and validity of the modified 7-day lee chronic graft-versus-host disease symptom scale
. Biol Blood Marrow Transplant
. 2020
;26
(3
):562
-567
.30.
Johnson
SR
, Hawker
GA
, Davis
AM
. The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: an evaluation of their measurement properties
. Arthritis Rheum
. 2005
;53
(2
):256
-262
.31.
Man
A
, Correa
JK
, Ziemek
J
, Simms
RW
, Felson
DT
, Lafyatis
R
. Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis
. Ann Rheum Dis
. 2017
;76
(8
):1374
-1380
.32.
US Food and Drug Administration
. Guidance for industry. patient-reported outcome measures: use in medical product development to support labelling claims
. Accessed 11 January 2024. https://www.fda.gov/media/77832/download.33.
Patrick
DL
, Burke
LB
, Gwaltney
CJ
, et al. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument
. Value Health
. 2011
;14
(8
):967
-977
.34.
Tong
A
, Sainsbury
P
, Craig
J
. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups
. Int J Qual Health Care
. 2007
;19
(6
):349
-357
.35.
Ziemek
J
, Man
A
, Hinchcliff
M
, Varga
J
, Simms
RW
, Lafyatis
R
. The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis
. Rheumatology
. 2016
;55
(5
):911
-917
.36.
Chren
MM
, Lasek
RJ
, Flocke
SA
, Zyzanski
SJ
. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases
. Arch Dermatol
. 1997
;133
(11
):1433
-1440
.37.
Bakas
T
, McLennon
SM
, Carpenter
JS
, et al. Systematic review of health-related quality of life models
. Health Qual Life Outcome
. 2012
;10
:134
.38.
Cleeland
CS
. Symptom burden: multiple symptoms and their impact as patient-reported outcomes
. J Natl Cancer Inst Monogr
. 2007
;2007
(37
):16
-21
.39.
DeWalt
DA
, Rothrock
N
, Yount
S
, Stone
AA
; PROMIS Cooperative Group
. Evaluation of item candidates: the PROMIS qualitative item review
. Med Care
. 2007
;45
(5 suppl 1
):S12
-S21
.40.
Patrick
DL
, Burke
LB
, Gwaltney
CJ
, et al. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding
. Value Health
. 2011
;14
(8
):978
-988
.41.
Terwee
CB
, Prinsen
CAC
, Chiarotto
A
, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study
. Qual Life Res
. 2018
;27
(5
):1159
-1170
.42.
Kerr
C
, Nixon
A
, Wild
D
. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research
. Expert Rev Pharmacoecon Outcomes Res
. 2010
;10
(3
):269
-281
.43.
Terwee
CB
, Bot
SD
, de Boer
MR
, et al. Quality criteria were proposed for measurement properties of health status questionnaires
. J Clin Epidemiol
. 2007
;60
(1
):34
-42
.44.
Pavletic
SZ
, Martin
P
, Lee
SJ
, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host sisease: IV. Response Criteria Working Group report
. Biol Blood Marrow Transplant
. 2006
;12
(3
):252
-266
.45.
Kilgour
JM
, Wali
G
, Gibbons
E
, et al. Systematic review of patient-reported outcome measures in graft-versus-host disease
. Biol Blood Marrow Transplant
. 2020
;26
(5
):e113
-e127
.46.
Fry
A
, Mitchell
SA
, Wiener
L
. Considerations for conducting and reporting digitally supported cognitive interviews with children and adults
. J Patient Rep Outcomes
. 2021
;5
(1
):131
.2025
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal